TY - JOUR T1 - Daily physical activity significantly improves after endobronchial valve treatment in patients with emphysema JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2015.OA1767 VL - 46 IS - suppl 59 SP - OA1767 AU - Jorine E. Hartman AU - Karin Klooster AU - Dirk-Jan Slebos AU - Nick H.T. Ten Hacken Y1 - 2015/09/01 UR - http://erj.ersjournals.com/content/46/suppl_59/OA1767.abstract N2 - Background: Bronchoscopic lung volume reduction using endobronchial valves (EBV) is a promising treatment for patients with severe emphysema. Physical activity is an important factor for the autonomy of these patients. For the first time, we investigated the effect of EBV treatment on daily physical activity in patients with severe emphysema, also to assess its potential as efficacy outcome parameter in this patient group.Methods: EBV treatment was compared with standard medical care in a randomized controlled trial. Daily physical activity was measured for 7 days by a triaxial accelerometer (Dynaport, McRoberts) at baseline and at 6 months follow-up.Results: Forty-three patients (23%male, age 59±9years, FEV1 30±7%pred, steps 3563±2213per/day, locomotion time 66±35minutes/day) wore the accelerometer and were included in the analysis. Nineteen patients received EBV treatment ('EBV group') and 24 standard medical care ('controls'). After 6 months, the EBV group significantly (p<0.01) improved compared to the controls in steps per day (+1252 vs -148), locomotion time per day (+17 vs -1 minutes) and locomotion intensity (+4.6 vs –1.5% compared to baseline). Furthermore, a higher increase in steps per day was significantly associated with a stronger decrease in RV (r=-0.40, p=0.007), higher increase in FEV1 (0.41, p=0.006) and a higher increase in 6MWT (r=0.57, p<0.01).Conclusions: EBV treatment significantly improves daily physical activity level and intensity in patients with severe emphysema. We suggest that daily physical activity should be an important patient-centered clinical outcome variable in clinical trials investigating treatments for severe COPD. ER -